By Billy Candra 
A large new study suggests that tailoring breast cancer screening to a woman’s individual risk may be safer and more effective than relying on routine annual mammograms for everyone, marking a pivotal shift in the paradigm of cancer prevention and early detection. By matching screening frequency and modality to personal risk levels, researchers found it was possible to significantly reduce the likelihood of diagnosing more advanced cancers while still ensuring individuals receive the precise level of screening they need, thereby optimizing patient outcomes and healthcare resource allocation. This groundbreaking research, coordinated by the University of California, San Francisco (UCSF), challenges decades of established screening protocols and paves the way for a more nuanced, individualized approach to breast health.
The Evolution of Screening: From Age-Based to Risk-Stratified
For decades, breast cancer screening guidelines have largely been predicated on age, recommending routine mammograms for women starting at a certain age, typically 40 or 50, and continuing at fixed intervals. This universal approach, while instrumental in reducing breast cancer mortality rates, operated under the assumption that most women faced a relatively similar risk of developing the disease. However, advancements in medical understanding, particularly in genetics and epidemiology, have increasingly highlighted the vast heterogeneity in individual breast cancer risk. Factors ranging from family history and genetic mutations to lifestyle choices, hormonal exposures, and breast density can dramatically alter a woman’s susceptibility, rendering age alone an insufficient determinant for screening intensity.
Breast cancer remains the most commonly diagnosed cancer among women in the United States, excluding skin cancers, affecting approximately one in eight women over their lifetime. The societal and economic burden of this disease is immense, underscoring the critical need for effective and efficient screening strategies. The traditional, population-wide screening model, while having its merits, has also faced scrutiny for potential downsides, including overdiagnosis and overtreatment in low-risk individuals, and conversely, inadequate screening for those at higher risk who might benefit from earlier or more frequent interventions. The WISDOM study emerged from this context, seeking to provide empirical evidence for a more sophisticated, risk-adaptive model.
Unveiling the WISDOM Study: Methodology and Design
The findings are based on comprehensive data collected from 46,000 women across the United States who participated in the initial phase of the Women Informed to Screen Depending On Measures of Risk (WISDOM) study. Launched in 2016, the WISDOM study was meticulously designed to directly compare the efficacy and safety of traditional annual mammography with a novel screening strategy rooted in individual risk assessment. UCSF served as the coordinating center for this ambitious multi-institutional endeavor, bringing together a consortium of leading research and clinical sites.
Participants were rigorously categorized into four distinct risk groups using well-validated predictive models. This comprehensive risk evaluation incorporated a multitude of factors, moving beyond mere age to include:
- Age: Still a foundational factor, but integrated with other metrics.
- Genetic Information: Including specific pathogenic variants and polygenic risk scores.
- Lifestyle Factors: Such as diet, physical activity, alcohol consumption, and reproductive history.
- Health History: Personal medical history, including prior benign breast disease or radiation exposure.
- Breast Density: A known independent risk factor for breast cancer.
Based on this granular assessment, tailored screening recommendations were provided:
- Lowest Risk Group (26% of participants): Advised to delay screening until age 50 or until an algorithm indicated their risk had naturally escalated to that of a typical 50-year-old woman. This approach aimed to reduce unnecessary early screening for those with minimal risk.
- Average Risk Group (approximately 62% of participants): Recommended to undergo screening every two years, aligning with some existing guidelines for this demographic but based on a more precise risk calculation.
- Elevated Risk Group (8% of participants): Advised to receive annual mammograms, acknowledging their heightened susceptibility.
- Highest Risk Group (2% of participants): Recommended to receive screening twice a year, alternating between mammography and MRI, regardless of age. This intensive protocol recognized their significantly elevated risk, often due to strong genetic predispositions, and the need for more frequent and sensitive detection methods.
This structured, data-driven stratification allowed researchers to evaluate whether a personalized approach could indeed improve outcomes compared to the conventional uniform screening schedule.
Transformative Findings and Expert Endorsements
The study’s results, published on December 12 in the prestigious journal JAMA and concurrently presented at the San Antonio Breast Cancer Symposium, offer compelling evidence that the personalized approach is not only viable but superior. "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," asserted Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Dr. Esserman’s statement underscores the profound implications of the study, suggesting a paradigm shift that could fundamentally redefine how healthcare providers and patients approach breast cancer screening.
Crucially, the personalized screening strategy demonstrated its effectiveness without compromising safety. The study found that this approach did not lead to a higher rate of late-stage cancer diagnoses. This is a critical validation, as a primary concern with any new screening regimen is ensuring that it does not inadvertently delay detection of aggressive cancers. Instead, by concentrating resources and more intensive screening on those at highest risk, the personalized model proved capable of maintaining or even improving the detection of early-stage cancers where treatment is most effective.
The high acceptance rate among participants further bolsters the argument for personalized screening. Among women who opted into an observational group and chose their preferred screening strategy, a remarkable 89% selected the risk-based screening pathway. This strong patient preference indicates that women are receptive to and trust a more individualized approach to their health, particularly when it is grounded in comprehensive risk assessment.
Jeffrey A. Tice, MD, a UCSF professor of Medicine and co-author specializing in breast cancer risk assessment tools, emphasized the efficiency of this new model. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," Dr. Tice stated. This perspective highlights the potential for optimized resource allocation within healthcare systems, ensuring that limited screening resources are directed to where they can yield the greatest benefit, potentially reducing healthcare costs associated with unnecessary screening for low-risk individuals while enhancing surveillance for those truly needing it.
Expanding the Horizon of Genetic Testing
One of the most notable and impactful findings of the WISDOM study pertains to the critical role of genetic testing. The study uniquely offered genetic testing to all participants, irrespective of their family history of breast cancer. This departure from conventional guidelines, which typically restrict genetic testing to individuals with a strong family history or other specific indicators, yielded a startling revelation: 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported no family history of the disease.
This statistic is profoundly significant. Under current clinical guidelines, a substantial proportion of these women—those carrying high-risk genetic mutations like BRCA1 and BRCA2, or other pathogenic variants—would not typically qualify for genetic testing. Consequently, their elevated risk would remain undetected, leading to delayed or inadequate screening, and potentially missed opportunities for early intervention or preventative measures. The WISDOM study thus advocates for a broader, more inclusive approach to genetic screening as an integral component of comprehensive risk assessment.
Beyond well-known pathogenic variants, the study also pioneered the evaluation of smaller DNA changes, which can be aggregated into a polygenic risk score (PRS). PRS combines information from hundreds or thousands of common genetic variants, each contributing a small effect to overall risk, to generate a more refined and individualized risk prediction. This innovative approach significantly improved the precision of risk predictions within the study, leading to 12% to 14% of participants being reassigned to a different risk category. Such reassignments could mean the difference between biennial mammograms and annual screenings, or even the inclusion of MRI for surveillance.
Allison S. Fiscalini, MPH, of UCSF, director of the Athena Breast Health Network and the WISDOM study, underscored the transformative potential of these genetic findings. "This is one of the first studies to offer genetic testing to all women, regardless of family history," Fiscalini noted. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." The integration of both high-penetrance genetic variants and polygenic risk scores represents a leap forward in personalized medicine, allowing for an unprecedented level of granularity in risk stratification.
Personalized Prevention and Long-Term Implications
The personalized approach extends beyond merely adjusting screening frequency; it also encompasses customized prevention strategies for higher-risk women. Participants identified as having elevated or highest risk received bespoke guidance aimed at actively lowering their chances of developing breast cancer. This support included access to an online decision-making tool focused on breast health, providing evidence-based information and resources. Direct contact with a breast health specialist offered personalized counseling and support, addressing individual concerns and tailoring recommendations.
These recommendations spanned crucial lifestyle modifications, such as improving diet and increasing physical activity, which are known to influence cancer risk. Furthermore, discussions about medications that can help reduce breast cancer risk, such as tamoxifen or aromatase inhibitors, were initiated for eligible individuals. This holistic approach empowers women to take proactive steps in managing their breast health, moving beyond passive screening to active prevention.
The broader implications of the WISDOM study are profound and multifaceted. If adopted, its findings could lead to a significant overhaul of national and international clinical guidelines for breast cancer screening. This would necessitate a shift in clinical practice, requiring healthcare providers to incorporate comprehensive risk assessment, including genetic testing and lifestyle evaluation, into routine patient care. While the implementation of such a system would require substantial logistical and educational efforts, the potential benefits—reduced advanced cancer diagnoses, optimized patient care, and more efficient use of healthcare resources—are compelling.
The Road Ahead: WISDOM 2.0 and Continued Refinement
The researchers are not resting on their laurels. The journey toward fully optimized risk-based screening continues with the WISDOM 2.0 study, which is currently enrolling participants. The primary objective of this subsequent phase is to further refine risk assessment models, with a particular focus on better identifying women who face a higher likelihood of developing aggressive breast cancers. By enhancing this predictive capability, WISDOM 2.0 aims to ensure that these individuals receive even more precisely tailored screening and prevention strategies, designed to meet their long-term health needs and maximize their chances of positive outcomes.
The collaborative nature of the WISDOM study, involving numerous institutions and a diverse group of co-authors, highlights the scientific rigor and broad consensus behind its findings. Key contributors from UCSF include Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.
Additional investigators and institutions from across the globe contributed to this landmark research, including teams from UC Los Angeles, UC Irvine, UC San Diego, San Francisco VA Health Care System, Sanford Health in North Dakota, University of Chicago, Diagnostic Center of Miami, University of Alabama, Virginia Commonwealth University, Weill Cornell Medicine in New York, and the Karolinska Institutet in Stockholm.
The study received vital financial support from several prominent organizations, including the Patient Centered Outcomes Research Institute (PCORI), the National Cancer Institute (NCI) through grant R01CA237533, and the Breast Cancer Research Foundation (BCRF). Further funding sources are detailed in the published paper. As with all major research, potential conflicts of interest were disclosed; for instance, Dr. Esserman serves as a medical advisory panel member for Blue Cross Blue Shield and has received author fees from the UpToDate electronic medical information resource, with full disclosures for other investigators provided in the research publication.
The WISDOM study represents a monumental leap forward in personalized medicine, offering a scientifically validated pathway to more effective, safer, and resource-efficient breast cancer screening. Its findings are poised to fundamentally reshape public health strategies and clinical practice, moving towards an era where breast cancer prevention and early detection are as unique as the individuals they serve.
